TEST:

Tempus xR

P2, N=700, Not yet recruiting, UNC Lineberger Comprehensive Cancer Center

Our data suggest that MSI/dMMR CRCs harboring RASmut are less immunogenic and TiME contains a lower inflammatory profile than wild-type or BRAFV600E tumors. Further analysis and validation are required to confirm these findings.

"Tempus AI, Inc...today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its RNA-based Tempus xR IVD device. xR IVD will be offered as a life sciences tool to support drug development programs."

By comprehensive molecular characterization of UC, we observed distinct genomic alterations and tumor microenvironment patterns in UTUC and UCB. Further research is warranted to elucidate the clinical implications of these findings. We compared the genetic and immune features of upper tract and bladder cancers. Our study found key differences that could affect treatment decisions, such as specific gene changes and immune markers. These insights may help doctors personalize therapies and improve patient care.

Our results demonstrate that IPS is a generalizable multiomic biomarker that can be widely used clinically as a prognosticator of ICI-based regimens.

Among patients with metastatic NSCLC, 37% present with DDRmt tumors characterized by higher TMB, frequency of MSI-H, and changes in immune cell infiltrates. These findings provide insight into the immunogenic landscape of DDR-altered NSCLC and may inform biomarker selection and therapeutic strategies.

Additionally, WGS can identify unique SVs that may be missed by conventional methods and enables clinical benefits such as HLA typing for potential transplant (alloHCT) or diagnostic refinement by retroviral insertion (e.g. HTLV-1). These findings demonstrate the potential for integration of WGS into clinical practice to enhance personalized treatment strategies.

"This study aimed to predict patient outcomes to immune checkpoint inhibitors (ICI) by developing an integrated DNA/RNA ICI biomarker. A de-identified pan-cancer cohort from the Tempus multimodal real-world database was utilized to develop and validate the Immune Profile Score (IPS) algorithm that leverages Tempus xT (DNA sequencing) and xR (RNA sequencing). The researchers found that IPS status can be used to stratify patient cohorts and prognosticate ICI-treatment response....The team analyzed real-world imaging patterns from a cohort of 4,147 advanced cancer patients treated with immune checkpoint inhibitors (ICI) across five solid tumor types....Incorporating these patterns into a microsimulation model, the team demonstrated that using the molecular biomarker in conjunction with CT imaging provided substantial cost savings and reduced inappropriate therapy compared to imaging alone, with the most benefit observed in small cell lung cancer (SCLC) treated with ICI-chemotherapy."

In this large, real-world translational research cohort of pts with HR+ MBC, low-level AURKA copy number gain was common. These data report the first evidence suggesting that low-level amplifications in AURKA, which conventional sequencing platforms miss, can provoke meaningful changes in gene expression as assessed via RNA transcriptome analysis. Further, low-level AURKA amplifications predict inferior outcomes on CDK4/6i for pts with HR+ MBC.

"Ethics Approval Tempus AI, Inc. has been granted an IRB exemption (Advarra Pro00072742) permitting the use of de-identified clinical, molecular, and multimodal data in order to derive or capture results, insights, or discoveries."

Background NDI-101150, an oral, selective, small molecule inhibitor of HPK1, is being studied as monotherapy and in combination with pembrolizumab. Ethics Approval This multicenter study was approved by the relevant Ethics Board at each study site. All participants gave informed consent before taking part.

"Given updated diagnosis, definitive concurrent chemoradiation (CRT, 7000 cGy in 35 fractions) with weekly cisplatin was administered...NUT IHC staining was negative, as has been reported due to tissue fixation. With inconsistent diagnostic tools for an already rare malignancy, our case highlights the role early NGS can play in diagnosis of unique cases that can alter management."